KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Acquisitions (2016 - 2019)

Abbott Laboratories (ABT) has disclosed Acquisitions for 11 consecutive years, with $82.0 million as the latest value for Q2 2019.

  • Quarterly Acquisitions rose 355.56% to $82.0 million in Q2 2019 from the year-ago period, while the trailing twelve-month figure was $203.0 million through Jun 2019, down 95.17% year-over-year, with the annual reading at $17.2 billion for FY2017, 21378.75% up from the prior year.
  • Acquisitions hit $82.0 million in Q2 2019 for Abbott Laboratories, up from $78.0 million in the prior quarter.
  • In the past five years, Acquisitions ranged from a high of $13.0 billion in Q1 2017 to a low of $7.0 million in Q4 2016.
  • Historically, Acquisitions has averaged $2.0 billion across 5 years, with a median of $78.0 million in 2019.
  • Biggest five-year swings in Acquisitions: skyrocketed 59271.43% in 2017 and later crashed 99.81% in 2018.
  • Year by year, Acquisitions stood at $231.0 million in 2015, then crashed by 96.97% to $7.0 million in 2016, then surged by 59271.43% to $4.2 billion in 2017, then plummeted by 99.57% to $18.0 million in 2018, then skyrocketed by 355.56% to $82.0 million in 2019.
  • Business Quant data shows Acquisitions for ABT at $82.0 million in Q2 2019, $78.0 million in Q1 2019, and $18.0 million in Q2 2018.